Health care stocks were higher Friday afternoon, with the NYSE Health Care Index rising 1.5% and the Health Care Select Sector SPDR Fund (XLV) climbing 1.6%.
The iShares Biotechnology ETF (IBB) added 1.3%.
In corporate news, Johnson & Johnson (JNJ) received approval from the UK's Medicines and Healthcare products Regulatory Agency for guselkumab to treat Crohn's disease and ulcerative colitis. The shares rose 1%.
Novo Nordisk (NVO) stock fell 3% after the Danish drugmaker said Chief Executive Officer Lars Fruergaard Jorgensen agreed to step down amid market challenges and share price declines.
BioMarin Pharmaceutical (BMRN) agreed to buy Inozyme Pharma (INZY) for $270 million. Inozyme shares more than doubled, and BioMarin rose 1.9%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.